Search Result

Results for "

proteinuria

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (3) Angiotensin-converting Enzyme (ACE) (4) Apoptosis (4) Cannabinoid Receptor (1) Dynamin (1) E1/E2/E3 Enzyme (1) Endogenous Metabolite (2) Guanylate Cyclase (1) HIV Integrase (1) Integrin (1) Isotope-Labeled Compounds (1) Mineralocorticoid Receptor (2) Platelet-activating Factor Receptor (PAFR) (1) Reactive Oxygen Species (ROS) (4) Reference Standards (2) TRP Channel (1)
By Research Areas:	Cancer (1) Cardiovascular Disease (6) Endocrinology (2) Infection (1) Inflammation/Immunology (5) Metabolic Disease (8)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B1472

Deoxycorticosterone acetate 2 Publications Verification 11-Deoxycorticosterone acetate; DOC acetate; Cortexone acetate	Mineralocorticoid Receptor Endogenous Metabolite	Endocrinology
Deoxycorticosterone acetate (DOCA) is an adrenocortin, acts as a precursor to aldosterone. Deoxycorticosterone acetate is a mineralocorticoid receptor agonist. Deoxycorticosterone acetate can cause severe renal injury, including inflammation, fibrosis, glomerular damage, and proteinuria .

HY-122051

AC1903 1 Publications Verification	TRP Channel	Metabolic Disease
AC1903 is a specific and selective inhibitor of TRPC5 and has podocyte-protective properties. AC1903 does no effects on TRPC4 or TRPC6 currents and shows no off-target effects in kinase profiling assays. AC1903 suppresses severe proteinuria and prevents podocyte loss in focal segmental glomerulosclerosis (FSGS) rat model .

HY-B1472R

Deoxycorticosterone acetate (Standard) 2 Publications Verification 11-Deoxycorticosterone acetate(Standard); DOC acetate(Standard); Cortexone acetate (Standard)	Reference Standards Mineralocorticoid Receptor Endogenous Metabolite	Endocrinology
Deoxycorticosterone acetate (Standard) is the analytical standard of Deoxycorticosterone acetate. This product is intended for research and analytical applications. Deoxycorticosterone acetate (DOCA) is an adrenocortin, acts as a precursor to aldosterone. Deoxycorticosterone acetate is a mineralocorticoid receptor agonist. Deoxycorticosterone acetate can cause severe renal injury, including inflammation, fibrosis, glomerular damage, and proteinuria .

HY-B0093

Benazepril 2 Publications Verification CGS14824A free base	Angiotensin-converting Enzyme (ACE) Apoptosis Reactive Oxygen Species (ROS)	Cardiovascular Disease Cancer
Benazepril (CGS14824A free base) is an orally active angiotensin-converting enzyme (ACE) inhibitor to reduce angiotensin-II production. Benazepril inhibits oxidative stress and inhibits apoptosis by the PI3K/Akt signaling pathway. Benazepril improves diabetic nephropathy and decreases proteinuria. Benazepril can be used in the study of hypertension, heart failure and diabetic nephropathy .

HY-B0093A

Benazepril hydrochloride 2 Publications Verification CGS14824A	Angiotensin-converting Enzyme (ACE) Apoptosis Reactive Oxygen Species (ROS) Akt	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
Benazepril (CGS14824A) hydrochloride is an orally active angiotensin-converting enzyme (ACE) inhibitor to reduce angiotensin-II production. Benazepril hydrochloride inhibits oxidative stress and inhibits apoptosis by the PI3K/Akt signaling pathway. In addition, Benazepril hydrochloride improves diabetic nephropathy and decreases proteinuria. Benazepril hydrochloride can be used in the study of hypertension, heart failure and diabetic nephropathy .

HY-110206

AM6545	Cannabinoid Receptor	Metabolic Disease
AM6545 is a highly selective, brain-free (peripherally active) CB1 receptor antagonist (K_i=1.7 nM). AM6545 inhibits endocannabinoid signaling by competitively antagonizing CB1 receptors, inhibiting CB1-mediated appetite stimulation and inflammatory responses without affecting cAMP levels. AM6545 significantly reduces food intake and body weight in mice, while improving metabolic syndrome-related renal impairment (such as proteinuria, fibrosis) and insulin resistance. AM6545 can be used in the study of obesity and its complications .

HY-109136

Runcaciguat BAY 1101042	Guanylate Cyclase	Cardiovascular Disease Metabolic Disease
Runcaciguat (BAY 1101042) is a selective, orally active, allosteric activator of soluble guanylate cyclase (sGC) that specifically targets its oxidized and heme-free form. Runcaciguat binds to sGC in a histidine-dependent manner and restores cyclic guanosine monophosphate (cGMP) production under oxidative stress, independent of nitric oxide (NO) or heme. Runcaciguat exhibits renoprotective and cardioprotective activities, such as reduced proteinuria and improved renal function. Runcaciguat is primarily being studied in chronic kidney disease (CKD) associated with hypertension, diabetes, and metabolic disorders, as well as potential cardiovascular indications such as heart failure with preserved ejection fraction (HFpEF) .

HY-119035

R-75317	Platelet-activating Factor Receptor (PAFR)	Inflammation/Immunology
R-75317 is a specific platelet-activating factor (PAF) antagonist. R-75317 can prevent the decline in creatinine clearance (Ccr) in a rat model of glomerulonephritis induced by the injection of antibodies extracted from rabbits against rat glomerular basement membrane (GBM) antigens, delay the onset of proteinuria, and improve glomerular hypertrophy, mesangial matrix proliferation, and interstitial fibrosis. R-75317 may be useful in the study of glomerulonephritis .

HY-B0093AS

Benazepril-d5 hydrochloride CGS14824A-d₅ hydrochloride	Isotope-Labeled Compounds Angiotensin-converting Enzyme (ACE) Apoptosis Reactive Oxygen Species (ROS) Akt	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
Benazepril-d₅ hydrochloride is deuterium labeled Benazepril hydrochloride. Benazepril hydrochloride is an orally active angiotensin-converting enzyme (ACE) inhibitor to reduce angiotensin-II production. Benazepril hydrochloride inhibits oxidative stress and inhibits apoptosis by the PI3K/Akt signaling pathway. In addition, Benazepril hydrochloride improves diabetic nephropathy and decreases proteinuria. Benazepril hydrochloride can be used in the study of hypertension, heart failure and diabetic nephropathy .

HY-B0093AR

Benazepril hydrochloride (Standard) CGS14824A (Standard)	Reference Standards Angiotensin-converting Enzyme (ACE) Apoptosis Reactive Oxygen Species (ROS) Akt	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
Benazepril hydrochloride (Standard) is the analytical standard of Benazepril hydrochloride. This product is intended for research and analytical applications. Benazepril hydrochloride is an orally active angiotensin-converting enzyme (ACE) inhibitor to reduce angiotensin-II production. Benazepril hydrochloride inhibits oxidative stress and inhibits apoptosis by the PI3K/Akt signaling pathway. In addition, Benazepril hydrochloride improves diabetic nephropathy and decreases proteinuria. Benazepril hydrochloride can be used in the study of hypertension, heart failure and diabetic nephropathy .

HY-13306

Pyrintegrin 4 Publications Verification	Integrin	Metabolic Disease
Pyrintegrin is an β1-integrin agonist and a 2,4-disubstituted pyrimidine that promotes embryonic stem cells survival. Pyrintegrin enhances cell-extracellular matrix (ECM) adhesion-mediated integrin signaling. Pyrintegrin can be used as a podocyte-protective agent and has robustly adipogenic .

HY-160928

Smurf1 modulator-1	E1/E2/E3 Enzyme	Cardiovascular Disease
Smurf1 modulator-1 (Compound 20) is a selective inhibitor for Smad ubiquitination regulatory factor 1 (Smurf1), with IC₅₀ of 180 nM .

HY-123572

Bis-T-23 AG1717	Dynamin HIV Integrase	Infection Metabolic Disease Inflammation/Immunology
Bis-T-23 (AG1717), tyrphostin derivative, is an HIV-I integrase inhibitor. Bis-T-23 can promote actin-dependent dynamin oligomerization. Bis-T-23 can be used for the research of HIV and chronic kidney diseases (CKD) .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-B1472

Deoxycorticosterone acetate 2 Publications Verification 11-Deoxycorticosterone acetate; DOC acetate; Cortexone acetate	Structural Classification Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields Endocrinology Steroids	Mineralocorticoid Receptor Endogenous Metabolite
Deoxycorticosterone acetate (DOCA) is an adrenocortin, acts as a precursor to aldosterone. Deoxycorticosterone acetate is a mineralocorticoid receptor agonist. Deoxycorticosterone acetate can cause severe renal injury, including inflammation, fibrosis, glomerular damage, and proteinuria .

HY-B1472R

Deoxycorticosterone acetate (Standard) 2 Publications Verification 11-Deoxycorticosterone acetate(Standard); DOC acetate(Standard); Cortexone acetate (Standard)	Structural Classification Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields Endocrinology Steroids	Reference Standards Mineralocorticoid Receptor Endogenous Metabolite
Deoxycorticosterone acetate (Standard) is the analytical standard of Deoxycorticosterone acetate. This product is intended for research and analytical applications. Deoxycorticosterone acetate (DOCA) is an adrenocortin, acts as a precursor to aldosterone. Deoxycorticosterone acetate is a mineralocorticoid receptor agonist. Deoxycorticosterone acetate can cause severe renal injury, including inflammation, fibrosis, glomerular damage, and proteinuria .

HY-B0093

Benazepril 2 Publications Verification CGS14824A free base	Cardiovascular Disease Classification of Application Fields Disease Research Fields	Angiotensin-converting Enzyme (ACE) Apoptosis Reactive Oxygen Species (ROS)
Benazepril (CGS14824A free base) is an orally active angiotensin-converting enzyme (ACE) inhibitor to reduce angiotensin-II production. Benazepril inhibits oxidative stress and inhibits apoptosis by the PI3K/Akt signaling pathway. Benazepril improves diabetic nephropathy and decreases proteinuria. Benazepril can be used in the study of hypertension, heart failure and diabetic nephropathy .

Cat. No.	Product Name	Chemical Structure

HY-B0093AS

Benazepril-d5 hydrochloride
Benazepril-d₅ hydrochloride is deuterium labeled Benazepril hydrochloride. Benazepril hydrochloride is an orally active angiotensin-converting enzyme (ACE) inhibitor to reduce angiotensin-II production. Benazepril hydrochloride inhibits oxidative stress and inhibits apoptosis by the PI3K/Akt signaling pathway. In addition, Benazepril hydrochloride improves diabetic nephropathy and decreases proteinuria. Benazepril hydrochloride can be used in the study of hypertension, heart failure and diabetic nephropathy .

Benazepril-d5 hydrochloride

Benazepril-d₅ hydrochloride is deuterium labeled Benazepril hydrochloride. Benazepril hydrochloride is an orally active angiotensin-converting enzyme (ACE) inhibitor to reduce angiotensin-II production. Benazepril hydrochloride inhibits oxidative stress and inhibits apoptosis by the PI3K/Akt signaling pathway. In addition, Benazepril hydrochloride improves diabetic nephropathy and decreases proteinuria. Benazepril hydrochloride can be used in the study of hypertension, heart failure and diabetic nephropathy .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks